Inactivation of Zika virus in plasma and derivatives by four different methods

Wang, Yancui; Ren, Kai; Liao, Xinzhong; Luo, Guanwen; Leetrakool, Nipapan; Li, Shilin; Chen, Limin; Yang, Chunhui; Chen, Yongjun

doi:10.1002/jmv.25538

Cited by 11 publications

(7 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Methylene blue is able to intercalate into viral nucleic acid when illuminated with visible light and prevents transmission of pathogens. The illumination of methylene blue inactivated Zika, yellow fever, dengue, chikungunya, Ebola viruses and Middle East respiratory syndrome coronavirus in plasma [2] , [3] , [4] , [5] . Methylene blue can also demonstrate antimicrobial activities without photoactivation.…”

Section: Introductionmentioning

confidence: 99%

Methylene blue inhibits replication of SARS-CoV-2 in vitro

Gendrot

Andréani

Duflot

et al. 2020

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Highlights Methylene blue 50% cytotoxicity concentration (CC 50 ) > 100 µM in Vero E6 cells. Methylene blue EC 50 of 0.3 ± 0.03 µM and EC 90 of 0.75 ± 0.21 µM at MOI of 0.25 against Vero E6 cells infected with SARS-CoV-2 strain (IHUMI-3). In comparison, EC 50 and EC 90 of 1.5 and 3.0 µM for hydroxychloroquine and 20.1 and 41.9 µM for azithromycin. C max /EC 50 and C max /EC 90 ratios in blood for methylene blue after oral administration were estimated at 10.1 and 4.0, respectively, and 33.3 and 13.3 after intravenous administration. Methylene blue EC 50 and EC 90 consistent with concentrations observed in human blood. Methylene blue inhibited SARS-CoV-2 replication in Vero E6 cells.

show abstract

Section: Introductionmentioning

confidence: 99%

Methylene blue inhibits replication of SARS-CoV-2 in vitro

Gendrot

Andréani

Duflot

et al. 2020

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

show abstract

“…Its antiviral proprieties have been attributed to its ability to intercalate into nucleic acids and inactivate RNA viruses. Virus inactivation with Methylene blue was applied in plasma to mitigate the risk of transmission by transfusion in human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus and Zika virus [ 40 , 41 ]. Methylene blue (also known as Provayblue) is indicated by FDA for the treatment of acquired methemoglobinemia.…”

Section: Discussionmentioning

confidence: 99%

A protein interaction map identifies existing drugs targeting SARS-CoV-2

Cava

Bertoli

Castiglioni

2020

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

Background: Severe acute respiratory syndrome coronavirus (SARS-CoV-2), an emerging Betacoronavirus, is the causative agent of COVID-19. Angiotensin converting enzyme 2 (ACE2), being the main cell receptor of SARS-CoV-2, plays a role in the entry of the virus into the cell. Currently, there are neither specific antiviral drugs for the treatment or preventive drugs such as vaccines. Methods: We proposed a bioinformatics analysis to test in silico existing drugs as a fast way to identify an efficient therapy. We performed a differential expression analysis in order to identify differentially expressed genes in COVID-19 patients correlated with ACE-2 and we explored their direct relations with a network approach integrating also drug-gene interactions. The drugs with a central role in the network were also investigated with a molecular docking analysis. Results: We found 825 differentially expressed genes correlated with ACE2. The protein-protein interactions among differentially expressed genes identified a network of 474 genes and 1130 interactions. Conclusions: The integration of drug-gene interactions in the network and molecular docking analysis allows us to obtain several drugs with antiviral activity that, alone or in combination with other treatment options, could be considered as therapeutic approaches against COVID-19.

show abstract

“…Several psychotropic drugs have been associated with antiviral and antitumor properties, suggesting that they may lower the severity of COVID-19 critical illness [16]. For example, imipramine, clomipramine and the phenothiazine class of drugs have demonstrated efficacy against other viruses, including Ebola, Dengue and West Nile [17][18][19][20]. In addition, thioridazine, another phenothiazine, was found to slow the progression of lung cancers, probably by enhancing antitumor immunity [21].…”

Section: Covid-19 and Psychotropic Drugsmentioning

confidence: 99%

COVID-19: A Catalyst for Novel Psychiatric Paradigms - Part 1

Sfera¹,

Osorio²,

Maldonado³

et al. 2022

Biotechnology to Combat COVID-19

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in the late 2019 and spread rapidly throughout the world, becoming a pandemic in March 2020. It became obvious early that the prognosis of this illness is highly variable, ranging from few mild symptoms to severe complications and death, indicating that aside from the pathogen virulence, host factors contribute significantly to the overall outcome. Like SARS-CoV and Human Coronavirus NL63 (HCoV-NL63-NL63), SARS-CoV-2 enters host cells via several receptors among which angiotensin converting enzyme-2 (ACE-2) are the most studied. As this protein is widely expressed in the lungs, blood vessels, brain, kidney, testes and ovaries, the effects of this virus are widespread, affecting many body tissues and organs. Viral attachment to ACE-2 downregulates this protein, disrupting angiotensin II (ANG II) hydrolysis that in return contributes to the unchecked accumulation of this peptide. ANG II toxicity is the result of excessive activation of ANG II type 1 receptors (AT-1Rs) and N-methyl-D-aspartate NMDA receptors (NMDARs). Overstimulation of these proteins, along with the loss of angiotensin (1–7) (ANG 1–7), upregulates reactive oxygen species (ROS), inflicting end-organ damage (hit 1). However, a preexistent redox impairment may be necessary for the development of SARS-CoV-2 critical illness (hit 2). Here we propose a two-hit paradigm in which COVID-19 critical illness develops primarily in individuals with preexistent antioxidant dysfunction. Several observational studies are in line with the two hit model as they have associated poor COVID-19 prognosis with the hereditary antioxidant defects. Moreover, the SARS-CoV-2 interactome reveals that viral antigen NSP5 directly inhibits the synthesis of glutathione peroxidase (GPX), an antioxidant enzyme that along with glucose-6-phosphate dehydrogenase (G6PD) protect the body from oxidative damage. Indeed, individuals with G6PD deficiency have less favorable COVID-19 outcomes compared to the general population.

show abstract

Inactivation of Zika virus in plasma and derivatives by four different methods

Cited by 11 publications

References 44 publications

Methylene blue inhibits replication of SARS-CoV-2 in vitro

Methylene blue inhibits replication of SARS-CoV-2 in vitro

A protein interaction map identifies existing drugs targeting SARS-CoV-2

COVID-19: A Catalyst for Novel Psychiatric Paradigms - Part 1

Contact Info

Product

Resources

About